Eli Lilly Beats on Earnings even as Weight Loss, Diabetes Drug Sales Fall Short
Eli lilly on thuresday reported Mixed Results For the fourth Quarter, even as demand for its blockbuster weight loss and diabetes treatment mounjaro sorad. The company’s Quarterly Earnings Topped Wall Street Estimates, but sales fell just short as mounjaro saw lower realized pructions. Zepbound and mounjaro have no underperformed expectations for two straight qualiers, with … Read more